Evolution of Anti-Cancer Treatment and its Impact on Surrogate Prognostic Factors in Multiple Myeloma
Aim. To assess prognostic value of surrogate clinical and laboratory markers in current therapy of multiple myeloma (MM). Materials & Methods. The analysis included 567 patients (215 men and 352 women), the Kirov region inhabitants with newly diagnosed MM over the period from January 1, 1994...
Saved in:
| Main Authors: | AS Luchinin, SV Semochkin, NV Minaeva, NM Pozdeev, IV Paramonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2018-04-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/03/6.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS
by: A. S. Luchinin, et al.
Published: (2017-10-01) -
Modern strategies in therapy of elderly patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01) -
Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma
by: SV Samarina, et al.
Published: (2019-09-01)